ClinicalTrials.gg
WithdrawnNCT06952686COMPASSUpdated Aug 6, 2025

A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants

A Phase 3 interventional study of SRP-9005 and Corticosteroid in Muscular Dystrophies, Limb-Girdle, sponsored by Sarepta Therapeutics, Inc.. Withdrawn at 1 site in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
Study was Withdrawn per Sponsor decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Muscular Dystrophies, Limb-Girdle · United States.

Enrollment
17th of 17
0 · median 11
Started
2025
with 1 other
Phase 3
3 of 30
none open now
Registered
30th of 30
by date
Lead sponsor
8 of 30
Sarepta Therapeutics, Inc.

Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, this one is the 17th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 3, and was the 30th registered.

Muscular Dystrophies, Limb-Girdle

47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.

Browse Muscular Dystrophies, Limb-Girdle studies →

Open to participants now

3 of the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Muscular Dystrophies, Limb-Girdle studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, or all of them as a file.
02

Study summary

This is a study of a single systemic dose of SRP-9005 in pediatric and adult participants with limb girdle muscular dystrophy type 2C/R5 (LGMD2C/R5). It is comprised of 2 parts (Part A, Part B) that will assess safety and efficacy.

03

Conditions studied

  • Muscular Dystrophies, Limb-Girdle

Keywords

  • SRP-9005
  • Type 2C/R5
  • LGMD2C/R5
  • Pediatric
  • Non-ambulatory
  • Ambulatory
  • Phase 1
  • Phase 3
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ambulatory, defined as able to walk without assistive aid, 10MWR \<30 seconds, and NSAD total score ≥20
  • Non-ambulatory, defined as 10MWR ≥30 seconds or unable to perform, and PUL 2.0 entry scale score ≥3
  • Possess 1 homozygous or 2 heterozygous pathogenic and/or likely pathogenic gamma-SG deoxyribonucleic acid (DNA) gene mutations as documented prior to pre-Infusion screening. Results to be confirmed by sponsor at a CLIA/CAP/ISO15189 certified laboratory prior to dosing.
  • Have AAVrh74 antibody titers \<1:400 (that is, not elevated) as determined by an enzyme-linked immunoassay

Key Exclusion Criteria:

  • Has a symptomatic infection (for example, upper respiratory tract infection, pneumonia, pyelonephritis, meningitis) within 4 weeks before study treatment infusion
  • Part A: Has (LVEF) \<50% on the screening echocardiogram (ECHO) (without use of cardiac medication) or clinical signs and/or symptoms of cardiomyopathy or any history of cardiac disease
  • Part B: Has LVEF \<40% on the screening ECHO or clinical signs and/or symptoms of cardiomyopathy
  • Has FVC \<40% of predicted value at screening and/or requirement for nocturnal ventilation
  • Serological evidence of current, chronic, or active infection, or or C infection or active viral or bacterial infection based on clinical observations
  • Any prior treatment with gene therapy, cell-based therapy (for example, stem cell transplantation), clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9), or any other form of gene editing
  • Treatment with human growth factor within 3 months of Day 1
  • Treatment with any medication within 6 months of the screening visit
  • Is unable to undergo or tolerate a cardiac MRI procedure for any reason

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    SRP-9005

    Participants will receive a single intravenous (IV) infusion of SRP-9005.

    Biological: SRP-9005 · Drug: Corticosteroid

Interventions

  • BiologicalSRP-9005

    Solution for single IV infusion

    Also known as: rAAVrh74.MHCK7.hSGCG

  • DrugCorticosteroid

    Oral tablet (prophylactic)

    Also known as: Prednisone or equivalent

06

What researchers measure

Primary outcomes

  1. Part A : Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline through Month 60

  2. Part A and B: Change from Baseline in gamma-Sarcoglycan (SG) Expression at Day 60 Post-dose in Ambulatory Participants as Measured by Immunofluorescence (IF) Percent Positive Fibers (PPF)

    Time frame: Baseline, Day 60

Secondary outcomes

  1. Part A and B: Change from Baseline Through Month 60 in North Star Assessment for Dysferlinopathy (NSAD) Total Score

    Time frame: Baseline through Month 60

  2. Part A and B: Change from Baseline Through Month 60 in Performance of the Upper Limb (PUL) Version 2.0 Total Score

    Time frame: Baseline through Month 60

  3. Part A and B: Change from Baseline through Month 60 in Time to Rise From Floor

    Time frame: Baseline through Month 60

  4. Part A and B: Change from Baseline Through Month 60 in Time to Ascend 4 Steps

    Time frame: Baseline through Month 60

  5. Part A and B: Change from Baseline Through Month 60 in Time to Complete the 10-meter Walk/Run (10MWR)

    Time frame: Baseline through Month 60

  6. Part A and B: Change from Baseline Through Month 60 in Time to Complete 100-meter Walk/Run (100MWR)

    Time frame: Baseline through Month 60

  7. Part A and B: Change from Baseline Through Month 60 in Timed Up and Go

    Time frame: Baseline through Month 60

  8. Part A and B: Change from Baseline in gamma-SG Expression at Day 60 in Ambulatory Participants Post-dose as Measured by IF Percent Fiber Intensity (PFI)

    Time frame: Baseline, Day 60

  9. Part A and B: Change from Baseline in gamma-SG Expression at Day 60 in Ambulatory Participants Post-dose as Measured by Western Assay

    Time frame: Baseline, Day 60

  10. Part A and B: Change from Baseline to Day 60 in Quantity of gamma-SG Protein Expression in Non-ambulatory Participants as Measured by IF PPF

    Time frame: Baseline to Day 60

  11. Part A and B: Change from Baseline to Day 60 in Quantity of gamma-SG Protein Expression in Non-ambulatory Participants as Measured by IF PFI

    Time frame: Baseline to Day 60

  12. Part A and B: Change from Baseline to Day 60 in Quantity of gamma-SG Protein Expression in Non-ambulatory Participants as Measured by Western Assay

    Time frame: Baseline to Day 60

  13. Part A and B: Change from Baseline to Month 24 in Quantity of gamma-SG Protein Expression as Measured by IF PPF

    Time frame: Baseline to Month 24

  14. Part A and B: Change from Baseline to Month 24 in Quantity of gamma-SG Protein Expression as Measured by IF PFI

    Time frame: Baseline to Month 24

  15. Part A and B: Change from Baseline to Month 24 in Quantity of gamma-SG Protein Expression as Measured by Western Assay

    Time frame: Baseline to Month 24

  16. Part A and B: Change from Baseline Through Month 60 in Creatine Kinase Levels

    Time frame: Baseline through Month 60

  17. Part A and B: Loss of Ambulation

    Time frame: Baseline through Month 60

  18. Part A and B: Change from Baseline Through Month 60 in Skeletal Muscle Magnetic Resonance Imaging (MRI)

    Time frame: Baseline through Month 60

  19. Part A and B: Change from Baseline Through Month 60 in Wearable Device Stride Velocity 95th Percentile (SV95C) (Ambulatory Participants Only)

    Time frame: Baseline through Month 60

  20. Part A and B: Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Forced Vital Capacity (FVC)

    Time frame: Baseline through Month 60

  21. Part A and B: Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Forced Vital Capacity Percent Predicted (FVC%p)

    Time frame: Baseline through Month 60

  22. Part A and B: Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: Baseline through Month 60

  23. Part A and B: Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Forced Expiratory Volume in 1 Second % Predicted (FEV1%p)

    Time frame: Baseline through Month 60

  24. Part A and B: Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Peak Expiratory Flow Rate (PEFR)

    Time frame: Baseline through Month 60

  25. Part A and B: Change from Baseline through Month 60 in Pulmonary Functions as Assessed by Maximal Inspiratory Pressure (MIP)

    Time frame: Baseline through Month 60

  26. Part A and B: Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Percent Predicted Maximal Inspiratory Pressure (MIP%p)

    Time frame: Baseline through Month 60

  27. Part A and B: Change from Baseline through Month 60 in Pulmonary Functions as Assessed by Maximal Expiratory Pressure (MEP)

    Time frame: Baseline through Month 60

  28. Part A and B: Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Percent Predicted Maximal Expiratory Pressure (MEP%p)

    Time frame: Baseline through Month 60

  29. Part B: Number of Participants with TEAEs

    Time frame: Baseline through Month 60

07

Study locations

1 site
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23510, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Nov 2030, 65 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2025
First posted
May 1, 2025
StartEst.
Jun 30, 2025
Primary completionEst.
Nov 30, 2030
CompletionEst.
Mar 30, 2032
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06952686
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Jun 30, 2025 (estimated)
Primary completion
Nov 30, 2030 (estimated)
Completion
Mar 30, 2032 (estimated)
Last update
Aug 6, 2025

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion